Skip to main content
$21.33 $0.01 (0.0%)

11:51 AM EST on 01/22/21

Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 5 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Current Price $21.33 Mkt Cap $6.6B
Open $21.23 P/E Ratio 42.98
Prev. Close $21.32 Div. (Yield) $0.00 (0.0%)
Daily Range $21.13 - $21.45 Volume 354,971
52-Wk Range $13.67 - $27.80 Avg. Daily Vol. 2,540,579

Caps

How do you think NASDAQ:EXEL will perform against the market?

Add Stock to CAPS Watchlist

All Players

2,469 Outperform
95 Underperform
 

All-Star Players

561 Outperform
23 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:EXEL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

MrUrban (84.82)
Submitted July 25, 2020

First one i picked all by myself, reason: 1. Mkt Cap 7.39B plenty place to grow2. EPS nxt Yr 94.84%3.EPS nxt 5Yr 46.00%4. Sales past 5Yr 107.60%5. Dept/ Equity 0Issues:1. High insider transactions almost 30%2. Company works on cure for cancer - high… More

BRADYstocks (27.14)
Submitted February 26, 2008

This sector is a scary one! Fear, though, is a fools game. I don't expect this stock to move upwards in the very near future. The cash burn is, well, similar to that Texas A&M bonfire tradition.

NASDAQ:EXEL VS S&P 500 (SPY)

Fools bullish on NASDAQ:EXEL are also bullish on:

Fools bearish on NASDAQ:EXEL are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about EXEL.

Recs

1
Member Avatar MrUrban (84.82) Submitted: 7/24/2020 8:04:22 PM : Outperform Start Price: $24.73 NASDAQ:EXEL Score: -32.76

First one i picked all by myself, reason:
1. Mkt Cap 7.39B plenty place to grow
2. EPS nxt Yr 94.84%
3.EPS nxt 5Yr 46.00%
4. Sales past 5Yr 107.60%
5. Dept/ Equity 0

Issues:
1. High insider transactions almost 30%
2. Company works on cure for cancer - high volatility
3. EPS this Y -53.80% but justified by Covid-19

Practice and enjoy!

Recs

0
Member Avatar TMFAdriaCimino (62.96) Submitted: 6/26/2020 9:09:05 AM : Outperform Start Price: $23.50 NASDAQ:EXEL Score: -34.48

The company's lead molecule, cabozantinib, has the potential for four new indications in the next year or so. And revenue is already climbing at Exelixis thanks to this molecule for kidney and liver cancers.

Recs

0
Member Avatar JagguShaik (< 20) Submitted: 6/15/2020 12:24:18 AM : Outperform Start Price: $19.96 NASDAQ:EXEL Score: +0.75

CABO with excellent CR (complete response) without any adverse events making decent money in the approved target conditions. Trails underway in > dozen conditions

Leaderboard

Find the members with the highest scoring picks in EXEL.

Score Leader

beave35

beave35 (77.22) Score: +1,456.61

The Score Leader is the player with the highest score across all their picks in EXEL.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Playa14 41.36 12/26/2014 12/5/2019 Outperform 5Y $1.27 +1,579.53% +83.75% +1,495.78 0 Comment
beave35 77.22 12/23/2014 Outperform 5Y $1.30 +1,540.64% +84.03% +1,456.61 0 Comment
tomkao < 20 12/15/2014 Outperform 5Y $1.40 +1,423.57% +89.88% +1,333.69 0 Comment
jack0071 74.17 12/3/2014 Outperform 5Y $1.43 +1,391.61% +84.65% +1,306.96 0 Comment
portefeuille 98.79 12/15/2014 Outperform 5Y $1.44 +1,381.25% +89.51% +1,291.74 0 Comment
akoniec 30.67 10/9/2014 Outperform 3Y $1.55 +1,276.13% +94.96% +1,181.17 0 Comment
dcoyne13 49.13 9/16/2014 Outperform 5Y $1.62 +1,216.59% +91.48% +1,125.10 0 Comment
foolerhoff 87.64 1/6/2015 Outperform 5Y $1.64 +1,200.61% +89.41% +1,111.20 0 Comment
garisonmp3z < 20 1/5/2015 Outperform 5Y $1.67 +1,177.25% +87.48% +1,089.77 0 Comment
new2fool23 54.39 1/5/2015 Outperform 1Y $1.67 +1,177.25% +87.48% +1,089.77 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EXEL.